Sanofi Weighs Insmed Takeover | Target Worth $26.3B After 15% Jump

Sanofi is weighing a takeover of Insmed, the Bridgewater, New Jersey maker of Brinsupri, a Bloomberg report said; Insmed jumped 15% to a $26.3 billion market value while talks stay preliminary.

By the Numbers

$26.3B
Insmed market cap, Nov 19
15%
Insmed share jump on Sanofi report
$524.4M
Insmed Q3 2026 revenue
$400.1M
Insmed Brinsupri Q3 2026 sales
About $111.3B
Sanofi market value
Trace Cohen
By Trace Cohen · Value Add Pulse Markets Desk
Founder & Editor-in-chief, Value Add VC
3 min read
Sanofi Weighs Insmed Takeover | Target Worth $26.3B After 15% Jump: key figures
ShareXLinkedInEmail

THE RUNDOWN

1

Insmed's $26.3 billion market cap would make a Sanofi deal more than ten times its $2.2 billion Dynavax acquisition, a Pulse calculation.

2

Brinsupri reached $400.1 million in third-quarter sales, giving any buyer a US launch already running above $1 billion a year.

3

Insmed's equity value is nearly a quarter of Sanofi's own, so a deal would change the size of Sanofi rather than add a bolt-on.

4

Talks are preliminary and other bidders could emerge, per Bloomberg, which leaves room for a contested process in large-cap biotech M&A.

The VC Read

Value Add VC analysis

A $26.3 billion public biotech priced on one US launch is the exit math late-stage and crossover biotech investors underwrite to: Brinsupri at $400.1 million a quarter is what a strategic will pay a premium for. The diligence item for any private comp is the deceleration Insmed shows, from 49% to 29% sequential growth; a buyer paying up here is betting the Japan launch restarts it, and private marks built on a still-accelerating curve should be haircut until a bid is on the table.

Analysis

As of Thursday, November 19, 2026, Sanofi is weighing an acquisition of Insmed, a deal for a company with a $26.3 billion market cap, Bloomberg reported, citing people familiar with the matter. Sanofi is speaking with advisers, deliberations are ongoing and any transaction could still be weeks away, according to the report as summarized by Seeking Alpha on TradingView. Insmed soared 15% and Sanofi's ADRs fell 3%. There is no guarantee of a deal, other bidders could emerge, and both companies declined to comment to Bloomberg.

What Insmed does

Insmed is headquartered in Bridgewater, New Jersey, and sells two drugs: BRINSUPRI (brensocatib) and ARIKAYCE (amikacin liposome inhalation suspension), per the company's first-quarter 2026 results release. Brinsupri is the reason a buyer would pay up: in that release Insmed guided to at least $1 billion of Brinsupri revenue for 2026.

Insmed revenue: how fast is Brinsupri growing?

The third quarter showed the launch still growing in dollars, with nearly all Brinsupri sales in the U.S. and a Japan launch in October, The Private Banker reported. The quarter by quarter numbers:

“Brinsupri is the reason a buyer would pay up: in that release Insmed guided to at least $1 billion of Brinsupri revenue for 2026.”

  • Q1 2026 -- total revenue $306.0 million; Brinsupri $207.9 million, Arikayce $98.1 million (Insmed release)
  • Q2 2026 -- Brinsupri $309.2 million (The Private Banker)
  • Q3 2026 -- total revenue up 268% to $524.4 million; Brinsupri $400.1 million, up 29% sequentially; Arikayce $124.4 million, up 9% year over year (The Private Banker)
  • 2026 Brinsupri guidance -- raised at the low end to $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion (The Private Banker)

The growth rate is slowing, though. Brinsupri's two prior post-launch quarters grew 44% and 49% sequentially, against 29% in the third quarter, and Insmed posted a loss of $0.46 a share, wider than the $0.34 analysts expected, per the same report.

Why Sanofi wants a US growth asset

Sanofi's growth leans on one drug. Dupixent sales rose 37.6% to EUR 5.2 billion in the second quarter of 2026, above EUR 5 billion a quarter for the first time, Sanofi reported. An Insmed deal would be a different size from the deals Sanofi usually does: Sanofi's market value is about EUR 101.3 billion, or $111.3 billion, so Insmed's equity value is nearly a quarter of Sanofi's, per The Private Banker, which noted that Sanofi's past bolt-on deals typically ran to a few billion dollars.

Value Add VC data

Insmed is a public company, so there are no recent private rounds to list, and no takeover price has been set. Comparable deals:

  • Sanofi and Dynavax -- Sanofi completed a $2.2 billion acquisition of the vaccines company (DCAT Value Chain Insights)
  • Palo Alto Networks and Applied Compute -- a $4.5 billion agreement this week, outside pharma, as Pulse covered on Nov 18

A bid at or above Insmed's $26.3 billion market cap would be more than ten times the Dynavax price, a Pulse calculation.

The risk in a takeover report

A report is not a bid. No price, financing structure or other terms have been disclosed, per The Private Banker, and Bloomberg's sources said a deal could be weeks away. The 15% jump also prices in a premium on a stock that had fallen about 40% over the prior 12 months, per The Private Banker, so a buyer is paying for Brinsupri's trajectory at the point where sequential growth is cooling from 49% to 29%. Insmed is scheduled to present at the Evercore ISI 9th Annual Healthcare Conference on December 1, per Seeking Alpha, the next public venue where management could be asked about Sanofi.

ShareXLinkedInEmail

More from the Pulse archive: Big Tech coverage → · All topics

Key Sources

1 source

Reported by Bloomberg · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with The VC Read, a few times a week. Free to subscribe, no spam.

No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗

Read Next

BIG TECH
Palo Alto Agrees To Buy Applied Compute For $4.5B | 1.4x Its $3.25B Mark
BIG TECH$4.5B All-Stock Deal

Palo Alto Agrees To Buy Applied Compute For $4.5B | 1.4x Its $3.25B Mark

Palo Alto Networks agreed to buy Applied Compute, a post-training and inference platform for open-weight AI models, in an all-stock deal valued at $4.5 billion, about 1.4 times the startup's $3.25 billion valuation from early November.

BIG TECH
Microsoft Nears $500M AI Deal With ByteDance | Irking OpenAI
BIG TECH$500M (Reported)

Microsoft Nears $500M AI Deal With ByteDance | Irking OpenAI

Microsoft is reportedly in advanced talks to sell ByteDance about $500 million more in Azure services, mostly access to OpenAI models that OpenAI itself keeps away from most Chinese companies.

BIG TECH
Intel Sued Over 28.6% Crash | Suit Cites $23B Stock Sale At $95
BIG TECH$140B Market Value Lost

Intel Sued Over 28.6% Crash | Suit Cites $23B Stock Sale At $95

A Michigan pension fund sued Intel, CEO Lip-Bu Tan and CFO David Zinsner, saying the chipmaker hid a PC slump while selling $23 billion of stock at $95 a share before its 28.6% one-day drop.